Shares of Antares Pharma, Inc. (NASDAQ:ATRS) were up 7.4% on Thursday . The company traded as high as $1.92 and last traded at $1.89. Approximately 866,696 shares changed hands during mid-day trading, a decline of 45% from the average daily volume of 1,573,358 shares. The stock had previously closed at $1.76.

A number of analysts have recently weighed in on ATRS shares. Vetr raised shares of Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 target price on the stock in a research report on Monday, July 24th. Piper Jaffray Companies set a $4.00 target price on shares of Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, July 26th. HC Wainwright set a $5.00 target price on shares of Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, ValuEngine downgraded shares of Antares Pharma from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and two have issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $3.84.

The company has a quick ratio of 2.89, a current ratio of 3.34 and a debt-to-equity ratio of 0.69.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.03). The company had revenue of $15.10 million for the quarter, compared to analysts’ expectations of $14.01 million. Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The company’s revenue was up 11.9% on a year-over-year basis. sell-side analysts predict that Antares Pharma, Inc. will post -0.11 EPS for the current year.

In other Antares Pharma news, Director Thomas J. Garrity sold 30,000 shares of the company’s stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total transaction of $105,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Leonard S. Jacob sold 230,000 shares of the company’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $4.05, for a total transaction of $931,500.00. The disclosure for this sale can be found here. Insiders own 11.60% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp lifted its position in shares of Antares Pharma by 20.1% during the first quarter. Bank of New York Mellon Corp now owns 167,515 shares of the specialty pharmaceutical company’s stock worth $476,000 after purchasing an additional 28,029 shares during the last quarter. California Public Employees Retirement System increased its stake in shares of Antares Pharma by 14.4% during the first quarter. California Public Employees Retirement System now owns 934,300 shares of the specialty pharmaceutical company’s stock valued at $2,653,000 after buying an additional 117,300 shares during the period. Vanguard Group Inc. increased its stake in shares of Antares Pharma by 4.3% during the first quarter. Vanguard Group Inc. now owns 5,619,088 shares of the specialty pharmaceutical company’s stock valued at $15,958,000 after buying an additional 232,349 shares during the period. Geode Capital Management LLC increased its stake in shares of Antares Pharma by 4.8% during the first quarter. Geode Capital Management LLC now owns 958,234 shares of the specialty pharmaceutical company’s stock valued at $2,721,000 after buying an additional 43,629 shares during the period. Finally, Morgan Stanley increased its stake in shares of Antares Pharma by 153.3% during the first quarter. Morgan Stanley now owns 996,113 shares of the specialty pharmaceutical company’s stock valued at $2,829,000 after buying an additional 602,834 shares during the period. Institutional investors own 36.84% of the company’s stock.

WARNING: This story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/11/18/antares-pharma-inc-atrs-trading-up-7-4.html.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Receive News & Stock Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related stocks with our FREE daily email newsletter.